After the reports in the New England Journal of Medicine in June 2012 on the phase I studies of anti-PD-L1 and PD-1 antibodies amazed the whole oncology field [6,7], immune checkpoint inhibitory antibodies have become some of the most promising antibody drugs to treat several cancers in the clinic [8]. This evidence concerns the gene PDCD1 and cancer.